Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ruwan Parakrama"'
Autor:
Ruwan Parakrama, Elisha Fogel, Carol Chandy, Titto Augustine, Matt Coffey, Lydia Tesfa, Sanjay Goel, Radhashree Maitra
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in co
Externí odkaz:
https://doaj.org/article/88cb56e4959547eb97786d26285e1c57
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Pancreatic ductal adenocarcinoma (PDAC) accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths. Despite the lower prevalence relative to other solid tumors, it is one of the leading causes of cancer-related death
Externí odkaz:
https://doaj.org/article/ed0accf7b52e4252ad25ed661b1a9e4c
Autor:
Ruwan Parakrama, Baho Sidiqi, Lyudmyla Demyan, Shamsher Pasha, Danielle Pinto, Tiffany Zavadsky, Xianghui Zhou, Sunita Patruni, Adrianna Kapusta, Oliver Standring, Matthew J. Weiss, Joseph M. Herman, Daniel A. King
Publikováno v:
Cancer Research. 82:A022-A022
Optimal management of patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC) is controversial and variation exists within/across academic and healthcare systems. Herein we describe the initial results of a neoadjuvant therapy (N
Autor:
John Fallon, Lyudmyla Demyan, Oliver Standring, Emma Gazzara, Ruwan Parakrama, Daniel A King, Joseph Herman, Matthew J Weiss, Danielle DePeralta, Gary Deutsch
Publikováno v:
Journal of the American College of Surgeons. 236:S60-S60
Autor:
Dylan Cooper, Baho Sidiqi, Ruwan Parakrama, Lyudmyla Demyan, Shamsher Pasha, Danielle Pinto, Tiffany Zavadsky, Xianghui Zou, Sunita Patruni, Adrianna Kapusta, Oliver Standring, Jason Nosrati, Leila T Tchelebi, Matthew John Weiss, Joseph M. Herman, Daniel King
Publikováno v:
Journal of Clinical Oncology. 41:695-695
695 Background: Significant variation exists in the management of potentially resectable pancreatic ductal adenocarcinoma (PDAC) across healthcare systems. We describe the results of a newly implemented neoadjuvant therapy pathway (NATP) in New York
Autor:
Umang Shah, Matthew C. Coffey, Himanshu Kharkwal, Sanjay Goel, Allyson J. Ocean, Sengottuvel Viswanathan, Imran Chaudhary, M. H. Ghalib, Ruwan Parakrama, Radhashree Maitra
Publikováno v:
Molecular Cancer Therapeutics. 19:1148-1156
KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is syn
Publikováno v:
Journal of cellular immunology
In our recent publication [1], we have explored at the molecular level the consequences of reovirus administration to patients with KRAS mutated colorectal cancer (CRC). This was the first reported study where transcriptome assay was performed on KRA
Publikováno v:
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Pancreatic ductal adenocarcinoma (PDAC) accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths. Despite the lower prevalence relative to other solid tumors, it is one of the leading causes of cancer-related death
Publikováno v:
npj Precision Oncology, Vol 3, Iss 1, Pp 1-9 (2019)
NPJ Precision Oncology
NPJ Precision Oncology
Cancer is an important global issue with increasing incidence and mortality, placing a substantial burden on the healthcare system. Colorectal cancer is the third most common cancer diagnosed among men and women in US. It is estimated that in 2018 th
Autor:
Titto Augustine, Sanjay Goel, Lydia Tesfa, Carol Chandy, Radhashree Maitra, Ruwan Parakrama, Elisha Fogel, Matthew C. Coffey
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Background KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination